The current data supports beta 3 adrenergic agonists as the recommended pharmacological therapy for overactive bladder syndrome, according to this research. Mirabegron has an effectiveness profile equivalent to first-line antimuscarinics, as well as a benign adverse effect profile. In individuals who are at a higher risk of anticholinergic side effects, treatment with a beta-3 adrenergic agonist should be preferred. The effectiveness and tolerance of beta-3 adrenergic agonists in older OAB patients, whether treated alone or in combination with other antimuscarinics, have been repeatedly documented. Unless the symptoms are severe or refractory, mirabegron is a cost-effective treatment for OAB. Mirabegron combined with other medications has been shown to be effective in managing OAB symptoms without causing major side effects.
While beta-3 adrenergic agonists have benefits in the treatment of OAB, clinicians should undertake complete and cautious pre-treatment planning to maximize treatment benefits and adherence.
Reference:https://link.springer.com/article/10.1007/s11934-020-01003-z
